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Parkinson’s disease (PD) is a complex fatal chronic neurodegenerative 
disease most common in elderly people. The early genome-wide asso-
ciation studies (GWAS) found that the minor allele variant of PARK16 
rs708730 polymorphism is a significant protective factor for PD in Cau-
casian populations. However, these results cannot be repeated by the 
following studies in Caucasian populations and other populations. We 
considered that the inconsistency of the findings may be caused by the 
small-scale samples or the heterogeneity among different populations. 
Therefore, in this study, we synthesized the previous related GWAS 
studies through three authoritative sources, and used the large-scale sam-
ples (10,645 PD cases and 30,499 controls) to reevaluate the association 
between rs708730 polymorphism and PD. The results showed that there 
is no association between them in Asian ancestry population. While, in 
European ancestry population, we found that the minor allele variant (G) 
of rs708730 polymorphism is significantly associated with a decreased 
risk of PD. Collectively, our findings further verified the association of 
rs708730 with PD and show its genetic heterogeneity among different 
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1. Introduction
Parkinson’s disease (PD) is a chronic progressive complex neurodegenerative disorder, and it is com-mon in elderly people [1,2]. Particularly, the prev-
alence of PD in the people aged above 60 years is more 
than three times that in entire population [2]. Another study 
further showed a rising popularizing rate of PD with age 
(425 per 100,000 in individuals aged 60-69 years, 1087 
in 70-79 years, and 1903 in aged above 80 years) [3]. PD 
is characterized by the dopaminergic neurons prominent 
death in substantia nigra and Lewy body formation [4,5]. 
A previous study predicted that the newly diagnosed PD 
patients are expected to reach as many as 8.7-9.3 million 
by 2030 from 4.1-4.6 million in 2005 around the 15 most 
populous nations [6].
The variants in a specific gene region, which is des-
ignated as PARK16 (1q32), are considered to play an 
important role in pathogenesis of PD [7-9]. In this region, 
the single nucleotide polymorphism (SNP) rs708730 (G 
< A) was identified significantly associated with PD in 
Caucasian populations by a large-scale genome-wide 
association studies (GWAS) [10]. Particularly, Sanchez et 
al. collected and analyzed 14,075 Caucasian individuals 
(including 5,272 PD patients and 8,803 controls) from 
USA, Germany and UK by GWAS. They found that the 
rs708730 polymorphism minor allele variant (G) can re-
duce the risks of PD (odds ratio (OR)=0.90, P=1.59×10-
3) [10].
However, the consistent and inconsistent results for 
the effect of rs708730 variant on PD in USA, UK, Chi-
na, Japan and Korea populations have been reported by 
the subsequent studies. For example, by analyzing 2,000 
PD and 1986 control Caucasian subjects from USA, 
Hamza et al. also found that the rs708730 polymor-
phism minor allele variant is a protective factor for PD 
(OR=0.87, P=0.03) [11]. While according to the results 
of two independent studies, the rs708730 is found not 
associated with PD in UK (OR=0.98, P=0.82) [12] and 
China populations (OR=0.81, P=0.19) [13], respectively. 
Further, Satake et al. and Chung et al. selected 20,392 
(including 2,011 PD patients and 18,381 controls) and 
2,244 (including 1,036 PD patients and 1,208 controls) 
individuals from Japan and Korea, respectively, and they 
found that the minor allele of rs708730 are associated 
with an increased risk of PD (OR=1.33 and P=2.43×10-8 
for Japan population [14]; OR=1.22 and P=0.008 for Ko-
rea population [15]).
We considered that the inconsistency of the findings 
may be caused by the small-scale samples or the hetero-
geneity among dierent populations. To overcome these 
defects and enhance reliability of the results, we selected 
a more complete sample set by searching the PubMed, 
ClinicalKey and Google Scholar databases. The large-
scale samples include 10,645 PD patients and 30,499 
controls from nine related GWAS studies, which are 
involved in European and Asian ancestry populations. 
Then, according to the method used in the previous stud-
ies [16-24], we conducted a meta-analysis to reevaluated 
the association between rs708730 polymorphism and 
PD. Further, we explored the heterogeneity among dif-
ferent populations and assessed the association between 
rs708730 and PD in Asian and European ancestry popu-
lations, respectively.
2. Methods
2.1 Literatures Acquisition and Studies Selection
We selected all the possible studies by searching PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed) and ClinicalKey 
(https://www.clinicalkey.com/) databases, respectively, us-
ing the keywords: “Parkinson’s disease” and “rs708730”, 
or “Parkinson’s disease” and “PARK16”. We collected all 
these literatures from the two databases before the last up-
date on September 25 2018. And then, the Google Scholar 
(http://scholar.google.com/) was further used to query all 
the references of the studies and the articles citing these 
studies identified from PubMed and ClinicalKey databas-
es.
After that, the appropriate studies were identified ac-
cording to the following criteria: (1) The study is designed 
according to the case-control strategy. (2) The study eval-
uates the association of rs708730 polymorphism and PD. 
(3) The study provides the number of cases and controls. 
(4) The ethnicity of each individual in the study was pre-
sented clearly. (5) The number of rs708730 genotypes 
both in cases and controls are provided by the study or it 
provides enough data to calculate these. (6) The OR value 
with 95% confidence interval (CI) and the P value are 
provided by the study or it provides enough data to calcu-
late these.
2.2 Data Extraction
The following information from each of the selected stud-
ies was extracted: (1) The publication year and the first 
author of these studies. (2) The ethnicity and population 
of the participants in these studies. (3) The number of 
PD patients and healthy controls in these studies. (4) The 
genotype information of rs708730 both in the PD patients 
and healthy controls. (5) The association analysis results 
(OR value with 95%CI and P value) in these studies. (6) 
The genotyping platforms. For the genotypes, OR value 
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and the 95%CI as well as the corresponding P value, we 
worked them out using R program (http://www.r-project.
org/) if these informations didn’t be provided directly.
2.3 Genetic Model Choice
Among the two alleles G and A of the rs708730 polymor-
phism, G was the minor allele. According to the previous 
studies [25-29], the allele model (A allele versus G allele), 
the dominant model (AG+GG versus AA), the recessive 
model (GG versus AA+AG), and the additive model (AA 
versus GG) are the common genetic model for the asso-
ciation analysis. Given that only the genotyping data of 
A allele versus G allele are provided from the selected 
studies (shown in Table 1), the allele model was used to 
analyze the association between rs708730 polymorphism 
and PD in this study.
2.4 Heterogeneity Test
We chose the two common quantities, Cochran’s Q and 
I2, to measure the heterogeneity among the di erent ethnic 
groups in this study. Cochran’s Q approximately follows a 
chi-squared distribution whose degrees of freedom is k-1 
(where k is the number of studies), and the I2 value is cal-









which ranges from 0 to 100%. Usually, the low, moderate, 
high and extreme heterogeneity are tentatively assigned to 
the I2 value of <25%, 25-50%, 50-75% and >75%, respec-
tively. According to previous studies, when the I2>50% 
and P<0.01, the heterogeneity among different ethnic 
groups is deemed significant in this study [25-29].
2.5 Meta-analysis and Subgroup Analysis
Usually, there are two models (fixed e ect model and 
random e ect model) used for meta-analysis. According 
to the results of heterogeneity test, we used the random 
and the fixed e ect model in the meta-analysis when 
heterogeneity is significant or not, respectively [30]. In 
meta-analysis, we calculated the pooled OR value and its 
95%CI as well as the corresponding P value to measure 
the association between the rs708730 polymorphism 
and PD based on the Z test. The meta-analysis was per-
formed by the R package ‘meta’ (http://cran.r-project.
org/web/packages/meta/index.html). By most criteria, 
the threshold of significant association was set as 95%CI 
of OR value do not include 1 and. And then, we further 
split the original samples into European and Asian an-
cestry populations, and performed the meta-analyses in 
each subgroup, respectively.
2.6 The Sensitivity and Publication Bias Analysis 
By most criteria, we used the two methods, Begg’s test 
[60] and Egger’s test [61], to evaluate the publication bias 
in this allele model. When the P values are less than 0.05, 
we deemed the publication bias is significant. Then, the 
funnel plot was drawn to show the results of the pub-
lication bias analysis based on its asymmetry. Finally, 
we performed the sensitivity analyses. For this purpose, 
each of the selected studies was excluded from the whole 
sample orderly to assess the influence of these studies 
one by one.
3. Results
3.1 Study Collection and Data Acquisition
Through the keyword search in PubMed and ClinicalKey 
databases and the filtration according to these criteria 
(see Methods for details), we identified a total 5 arti-
cles and corresponding 9 studies in them which include 
10,645 PD cases and 30,499 controls from European and 
Asian ancestry populations. Moreover, another related 
study involved in Asian ancestry population was further 
obtained by checking the citation using Google Scholar. 
The workflow was shown in Figure 1. Then, we extracted 
the characteristics of these 9 studies, and the main con-
tents were exhibited in Table 1. Finally, we counted the 
rs708730 polymorphism genotype data of each study for 
the following meta-analysis (Table 2).
Figure 1. The flow chart of studies selection for re-evalu-
ating the association of SNP rs708730 with PD
DOI: https://doi.org/10.30564/jgm.v1i2.798
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3.2 Heterogeneity Test
Given that only the genotyping data of G and A allele are 
provided from the 9 studies, we first tested the heteroge-
neity of all these samples based on the allele model. We 
found a significant genetic heterogeneity of rs708730 
polymorphism among these selected samples (I2=83% and 
P<0.01). Therefore, according to the ethnicity of these 
samples, we further tested the rs708730 polymorphism 
heterogeneity in European and Asian ancestry populations, 
respectively. We also found a significant genetic hetero-
geneity of rs708730 polymorphism among Asian ancestry 
populations using the allele model (I2=90% and P<0.01). 
However, we did not identify the significant genetic het-
erogeneity among the European ancestry populations (I2=0 
and P=0.63).
3.3 Meta-analysis and Subgroup Analysis
Because we observed a significant heterogeneity for all 
these samples, we performed a meta-analysis to assess 
the association between rs708730 polymorphism and 
PD using the random e ect model. We have not found a 
significant association for the comprehensive population 
based on the allele model (OR=0.989, 95% CI=0.878-
1.115, P=0.875). The corresponding forest plot was de-
scribed in Figure 2. Given that the genetic heterogeneity 
of rs708730 polymorphism in the comprehensive popula-
tion is significant, we further divided these samples into 
Asian and European ethnicity subgroups. According to 
the results of heterogeneity, we performed the meta-anal-
yses using the fixed e ect and random e ect model for the 
European and Asian ancestry populations, respectively. 
Still, we have not observed a significant association 
between rs708730 polymorphism and PD in the Asian 
ancestry population (OR=1.055, 95% CI=0.811−1.372, 
P=0.689) (Figure 3a). However, the significant asso-
ciation was identified in the European ethnicity sub-
groups. Particularly, we found that the minor allele G of 
rs708730 polymorphism is significantly associated with 
a reduced risk of PD in European ancestry population 
Table 1. The main contents in the selected studies for this meta-analysis
Study Year Country Ethnicity No. of cases No. of controls Genotyping platform Kind of genotype
Sanchez et al.(Stage I) 2009 USA and Germany European 1,063 3,071 HumanHap550 G/A
Sanchez et al.(Stage II) 2009 USA, UK and Ger-many European 3,452 4,756 Illumina G/A
Pankratz et al. 2009 UK European 857 867 Illumina G/A
Hamza et al. 2010 USA European 2,000 1,986 Illumina G/A
Yan et al. 2011 China Asian 226 230 ABI 3100 automated sequencer G/A
Satake et al.(Stage I) 2009 Japan Asian 1,078 2,628 Illumina G/A
Satake et al.(Stage II) 2009 Japan Asian 612 14,139 VeraCode G/A
Satake et al.(Stage III) 2009 Japan Asian 321 1,614 TaqMan G/A
Chung et al. 2013 Korea Asian 1,036 1,208 Sequenom MassAR-RAY system G/A
All 10,645 30,499
Note: “G/A” means that the data of genotypes G and A are provided by the study both in cases and controls.
Table 2. the genotype information of the selected studies
Study Year Ethnicity Minor allele MAF in case/control PD.G TOTAL.G PD.A TOTAL.A
Sanchez et al.(Stage I) 2009 European G 0.15/0.17 319 1363 1807 6905
Sanchez et al.(Stage II) 2009 European G 0.16/0.17 1105 2722 5799 13694
Pankratz et al. 2009 European G 0.17/0.17 291 586 1423 2862
Hamza et al. 2010 European G 0.16/0.17 640 1315 3360 6657
Yan et al. 2011 Asian G 0.19/0.23 87 192 365 720
Satake et al.(Stage I) 2009 Asian G 0.14/0.18 302 1248 1854 6164
Satake et al.(Stage II) 2009 Asian G 0.15/0.17 1040 25077 184 4991
Satake et al.(Stage III) 2009 Asian G 0.12/0.18 565 3212 77 658
Chung et al. 2013 Asian G 0.19/0.22 1678 3563 394 925
Note: MAF: Minor allele frequency
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(OR=0.924, 95% CI=0.872−0.979, P=0.007) (Figure 
3b).
3.4 The Sensitivity and Publication Bias Analysis
After the Egger’s test and Begg’s test, we found no sig-
nificant publication bias in all these studies based on the 
allele model (Egger’s test, P=0.393, and Begg’s test, 
P=0.404). The results were described in a funnel plot 
(Figure 4). Moreover, we further excluded each study 
orderly to perform the sensitivity analysis. The results 
showed that the heterogeneity and the association be-
tween rs708730 polymorphism and PD have not changed 
significantly when excluding any of the studies from the 
whole. The detailed information was shown in the Table 
3.
Figure 4. The funnel plot showing the results of the publi-
cation bias analysis. 
Note: The allele genetic model is used for the association assessment 
between rs708730 polymorphism and PD.
Figure 2. The forest plot showing the results of the meta-analysis in allele model. 
Note: Because the genetic heterogeneity of rs708730 polymorphism in the comprehensive population is significant, we used the random effect model 
to perform the meta-analysis of all 9 selected studies in the allele contrast (G versus A)
Figure 3. The forest plot showing the results of the meta-analysis in subgroups. 
Note: (a) In Asian ancestry population, the significant association between rs708730 polymorphism and PD is not observed. While, (b) the minor al-
lele variant (G) of rs708730 polymorphism is significantly associated with a reduced risk of PD in European ancestry population.
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4. Discussion
PD is characterized by the Lewy body formation and 
dopaminergic neurons death in substantia nigra, and is 
most seen in elderly people [1-5]. The previous studies 
reported that a specific gene region, PARK16 (1q32), 
plays a key role in PD’s pathogenesis [7-9]. And then, the 
subsequent GWAS studies found that the SNP rs708730 
is in PARK16 and its minor allele variant (G) is a pro-
tective factor for PD in Caucasian populations [11,10]. 
However, these results cannot be repeated in China 
(OR=0.81, P=0.19) [13], Japan (OR=1.33, P=2.43×10-8) 
[14], Korea (OR=1.22, P=0.008) [15] and another Caucasian 
population (OR=0.98, P=0.82) [12]. We considered that 
the inconsistency of the findings may be caused by the 
small-scale samples or the heterogeneity among di erent 
populations. Therefore, after selecting and summarizing 
the related studies, the larger scale samples and more 
comprehensive population were used to explore the as-
sociation between rs708730 polymorphism and PD.
In this study, 9 related GWAS studies (involving in a 
total 10,645 PD cases and 30,499 controls from USA, UK, 
Germany, China, Japan and Korea) were selected through 
three authoritative public databases. Then, we re-evaluat-
ed the association between rs708730 polymorphism and 
PD in European and Asian ancestry ethnicity, respectively. 
The results showed that there is no association between 
rs708730 polymorphism and PD in Asian ancestry popu-
lation (OR=1.005, 95% CI=0.811−1.372 P=0.689). While, 
in European ancestry population, we found that the minor 
allele variant (G) of rs708730 polymorphism is signifi-
cantly associated with a reduced risk of PD (OR=0.924, 
95% CI=0.872−0.979 P=0.007). Moreover, we found that 
genetic heterogeneity of rs708730 polymorphism is signif-
icant on the whole (I2=83% and P<0.01). When we split 
the original samples into European and Asian ancestry 
populations, the genetic heterogeneity is still significant 
in Asian (I2=90% and P<0.01) but not European ancestry 
populations (I2=0 and P=0.63). So, the more similar asso-
ciation studies should be performed in more subgroups of 
Asian ancestry population.
To our knowledge, this meta-analysis selected the most 
comprehensive samples by far to explore the association 
between the PARK16 rs708730 polymorphism and PD. 
Our findings reveal a significant protective function of 
rs708730 minor allele variant for PD in European but not 
Asian ancestry populations, which have further verified 
the association between rs708730 and PD and also show 
its genetic heterogeneity among different populations. In 
summary, the findings of this study would help deepen 
cognition about pathogenesis of PD.
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